Use of aescin in the preparation of medicines for treating ulcerative colitis

A technology for ulcerative colitis and escin, which is applied in the field of escin in the field of preparing medicines for treating ulcerative colitis, can solve problems such as immune inflammation such as UC that have not yet been found, and achieve the effects of significant symptoms, symptom prevention and treatment

Active Publication Date: 2022-04-26
CHINA PHARM UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

We used a certain extraction method to extract and prepare the active ingredient aescin (Aescin) in the anti-ulcerative colitis activity from the seeds of Sala seed. So far, no information has been found about the active ingredient to treat or improve immune inflammation such as UC literature reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of aescin in the preparation of medicines for treating ulcerative colitis
  • Use of aescin in the preparation of medicines for treating ulcerative colitis
  • Use of aescin in the preparation of medicines for treating ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Detection of anti-ulcerative colitis drug components of the present invention

[0030] 1. Experimental method

[0031] The content of the main component of the aescin drug is determined, and HPLC is used for detection, and the chromatographic conditions are as follows:

[0032] Chromatographic column: Agilent 5HC-C18, 4.6*250mm, 5.0μm;

[0033] Column temperature: 30°C;

[0034] UV detection wavelength: 220nm;

[0035] Flow rate: 1.0ml / min;

[0036] Mobile phase: A, 0.1% phosphoric acid aqueous solution; B, acetonitrile;

[0037] Isocratic elution: B: 42%.

[0038] 2. Experimental results

[0039] The HPLC chromatograms of the main components are shown in figure 1 and content see figure 2 . The HPLC chromatogram of aescin and the chromatographic peak information table of each component are shown in the table. Among them, the content of the main component aescin A in aescin accounts for 30.42% of the total content, the content of aescin B accounts for 15.38% o...

Embodiment 2

[0041] Effect of anti-ulcerative colitis drug of the present invention on mouse UC model

[0042] 1. Test materials

[0043] 1.1 Drugs and dosage

[0044] The experimental drugs include one test drug and sulfasalazine as the positive control drug, and the specific dosage is shown in Table 2

[0045] Table 2. Tested drugs and dosage

[0046]

[0047] 1.2 Test animals

[0048] C57 mice, male, Center for Comparative Medicine, Yangzhou University, license number: SCXK (Su) 2017-0007.

[0049] 1.3 Test equipment

[0050] Ultrapure water preparation system; ordinary refrigerator; ultra-low temperature refrigerator; ice crusher; electronic balance.

[0051] 1.4 Solution preparation

[0052] (1) 2.5% DSS (w / v) solution: weigh 2.5g DSS powder, dissolve it in 100ml deionized water, and fully dissolve until the system is transparent.

[0053] (2) 0.01M PBS solution: weigh 0.2g KCl, 7.9g NaCl, 1.44g Na 2 HPO 4 and 1.8g K 2 HPO 4 , dissolved in 800ml of deionized water, adjus...

Embodiment 3

[0075] Aescin 100 mg, mixed with 50 mg of starch and 50 mg of dextrin, made into a soft material with an appropriate amount of 30% ethanol as a wetting agent, granulated by conventional methods, mixed with magnesium stearate, and made into tablets.

[0076] 50 mg of aescin is mixed with 70 mg of starch, 10 mg of dextrin, and 10 mg of powdered sugar, and 30% ethanol is used as a wetting agent to make a soft material, which is prepared into granules by wet granulation.

[0077] Aescin 100mg is mixed with starch 50mg and talcum powder 5mg to make powder by conventional technology.

[0078] 100 mg of aescin, 20 mg of powdered sugar and 5 mg of water are prepared into a syrup by conventional technology, and then 70 mg of starch is added to prepare a pill by conventional technology.

[0079] Aescin 100g is decocted twice with 1000g water by traditional decoction method, and the decoction is combined to make a decoction.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the use of aescin in the preparation of medicine for treating ulcerative colitis. Aescin obtained from the traditional Chinese medicine Su Luozi has the functions of clearing away heat, stopping bleeding, reducing inflammation, and dispelling blood stasis, and has significant preventive and therapeutic effects on abdominal pain, diarrhea, mucus, pus, and bloody stools caused by ulcerative colitis.

Description

technical field [0001] The invention discloses the use of a traditional Chinese medicine extract, in particular to the use of aescin in the preparation of medicines for treating ulcerative colitis. Background technique [0002] Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease that belongs to the category of autoimmune diseases. UC is refractory, prone to recurrence, deterioration and canceration, and has been listed as one of the modern intractable diseases by the World Health Organization (WHO). UC is a chronic non-specific inflammatory disease of the colon and rectum whose etiology is not yet clear, and the lesions are limited to the mucosa and submucosa of the large intestine. The lesions are mostly located in the sigmoid colon and rectum, and can also extend to the descending colon, or even the entire colon. The course of the disease is long and often recurrent. The disease is seen at any age, but it is most common in 20-30 years old. Diarrhea-ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P1/00A61K36/185
CPCA61K31/704A61P1/00A61K36/185
Inventor 刘丽芳李昊轩辛贵忠刘紫薇
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap